Direct answer:Establishment of mechanisms for the verification of information around facilities, responsible persons, product listing and contact details; Please refer to the current official requirements of the FDA, the nature of the document, its current status and the business proposals set out below; Specific products should be judged in the official language.

What is this file, at what stage?

This is an ongoing maintenance compliance check note and does not correspond to a single new release.

A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.

Which enterprises and products need attention?

Facilities responsible for the production or processing of cosmetics in the United States, brand owners and import chain-related enterprises.

It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.

Where is the change from what was previously requested?

This page does not claim new changes in uniform regulations, focusing on the consolidation of application requirements, division of responsibilities and official reconciliation paths into ongoing maintenance processes.

Establishment of mechanisms for the verification of information around facilities, responsible persons, product listing and contact details; Please refer to the current official request of the FDA.

This paper is used to help Chinese enterprises understand common problems and information preparation directions and does not constitute product-specific legal opinions, regulatory decisions or FDA approval commitments. Product requirements may vary according to category, purpose and role of the enterprise.

In determining regulatory requirements, it is recommended that the intended use, composition or technical characteristics of the product, labelling and market declarations, as well as the activities of enterprises such as production, packaging, import or sale, be organized first. Products with similar names may also be subject to different regulatory paths due to different uses and declarations.

  • Product name, use, component or technical information
  • Business roles of manufacturers, exporters, importers, brand parties, etc.
  • Target markets, distribution channels and current project phase
  • Existing registration, listing, declaration or transaction record

Identification of product categories will be followed by an official page, regulation, guidelines and database in the FDA counterpart area to determine whether they involve facility registration, product listing, labelling requirements, pre-market declaration or subsequent updates. Information requirements and operational access are not the same in different areas of regulation.

Establishment of a list of information

(c) To organize business identification information, facility information, product information, responsible party information and technical documents on a case-by-case basis. When information is available in English, check the consistency of terminology with label content; When the information is incomplete, list the items to be confirmed before moving forward.

Retention of submission and maintenance records

Establish account responsible persons and internal alert mechanisms to retain official records, confirm information and follow-up changes. Any renewal or updating arrangements should be verified in accordance with the current FDA rules and applicable dates.

  • To express registration, listing or filing as FDA approval or authentication.
  • It was felt that all enterprises in the same product category were required to handle the same projects.
  • The current requirements are judged only on the basis of the third-party summary or the old version of the guide.
  • The division of responsibilities between the different roles of manufacturers, brand parties, importers, etc. is ignored.

If you are evaluating the export arrangements, you can prepare the use, composition or specification of the product, the place of production, the role of the enterprise and the current stage, which can then be checked from official data. ALREG can assist in synthesizing and routing data according to the range of services.

Key dates and transitional arrangements

This page is an ongoing maintenance note and does not correspond to a single statutory document; The date of issuance of a single document, the date of closure of the opinion and the date of implementation do not apply. The specific period shall be subject to the official FDA document. The website’s article update date is not the date of implementation of the statute.

How can Chinese companies prepare?

  1. (c) The establishment of accounts, addresses, responsible persons, U.S. agent and product listing records by facility; Change of settings triggers review.
  2. Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
  3. If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.

For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.

Exceptions, pending confirmations and common misreading

  • This page maintains the reconciliation framework on an ongoing basis and does not correspond to a single new statute or uniform renewal date; Specific obligations and exemptions are subject to verification by facility and product.
  • When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
  • Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.

Official information and reconciliation records

This page is an account of ongoing maintenance; Please. FDA Official websiteEnter the corresponding product centre and regulatory page and check the current version. This paper does not substitute a third party summary for an official basis.

(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.

Next

Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.